Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FDA Approves Bayer AGs...

    FDA Approves Bayer AGs Five year contraceptive, Kyleena

    Written by savita thakur thakur Published On 2016-09-21T12:07:02+05:30  |  Updated On 21 Sept 2016 12:07 PM IST
    FDA Approves Bayer AGs Five year contraceptive, Kyleena

    The U.S. Food and Drug Administration approved Bayer AG's hormonal contraceptive device, Kyleena, to prevent pregnancy for up to five years, the German company said.


    The small, flexible plastic T-shaped intrauterine device (IUD) releases the hormone levonorgestrel that stops the womb lining from thickening, which in turn prevents pregnancy.


    Kyleena, which will be available from October, is a long-acting reversible contraceptive (LARC), a category of potent contraceptives that has returned to popularity.


    LARCs, including IUDs and implants, are more effective than other contraceptives such as pills and patches, and are nearly as effective as sterilization, according to the U.S. Centers for Disease Control and Prevention.


    Hormonal IUDs such as Kyleena are marginally more effective than commonly used copper IUDs, such as Teva Pharmaceutical Industries Ltd's Paragard, which last longer but do not help control blood flow.


    After using Kyleena for a while, women are likely to experience fewer days of bleeding and spotting, while periods will stop altogether for some, Bayer said.


    Kyleena adds to a suite of Bayer hormonal IUDs, including Mirena and Skyla.


    The FDA in February 2015 also approved Liletta, a hormonal IUD made by Actavis Plc, now known as Allergan Plc. Liletta is approved to prevent pregnancy for up to three years.

    allergenBayercontraceptiveFDA approvedintrauterine deviceIUDLARClong-acting reversible contraceptiveTevaUS Centers for Disease Control and PreventionUS Food & Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok